查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553641

儿科疫苗市场规模、份额、趋势分析报告：按类型、技术、应用、地区、细分市场预测，2024-2030 年

Pediatric Vaccines Market Size, Share & Trends Analysis Report By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines), By Application (Cancer), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

儿科疫苗市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球儿科疫苗市场规模将达到494.6亿美元，复合年增长率为4.1%。

疫苗开发和新产品推出的新兴市场开拓是市场的主要驱动因素。

公司增加投资以获得更大的市场占有率预计将推动成长。导致投资增加的因素包括新兴市场强劲的成长前景、医生强制执行的儿童免疫计划以及联合国儿童基金会和世界卫生组织等医疗保健组织主导的宣传计划。此外，政府加强提高免疫意识也有望推动儿科疫苗市场的发展。

新型佐剂和治疗性疫苗的开发进展预计将在预测期内推动成长。正在进行的针对体内特定作用机制的新型分子的研究旨在提供针对癌症和兹卡病毒感染疾病等致命疾病的免疫力。例如，2016年6月，Inovio Pharmaceuticals, Inc.宣布启动名为GLS-5700的兹卡病毒DNA疫苗的I期临床试验。

儿科疫苗市场报告亮点

  • 从类型来看，由于高使用率和政府活性化研发活动等因素，单价疫苗已成为最大的市场区隔。
  • 就 2023 年的销售额而言，结合疫苗将构成压倒性的技术领域。这些疫苗的高采用率和感染疾病病率的增加是儿科疫苗市场的主导因素。
  • 从应用来看，麻疹-流行性腮腺炎-德国麻疹(MMR) 领域预计在预测期内将以 6.1% 的最快复合年增长率成长。这是因为麻疹、腮腺炎和德国麻疹病例持续存在，这是免疫覆盖率低地区未接种疫苗的儿童的特征。
  • 2023 年，北美地区占据最大的销售份额。北美在儿科疫苗市场的主导地位是由于行业巨头在当地的存在以及广泛的研发活动等因素。
  • 由于感染疾病的流行和目标人口的增加，预计亚太地区在未来十年将出现良好的增长。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章儿科疫苗市场变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 儿科疫苗市场分析工具
    • 波特的分析
    • PESTEL分析

第四章儿科疫苗市场：按类型估计和趋势分析

  • 细分仪表板
  • 儿科疫苗市场：2023 年和 2030 年按类型分類的变化分析
  • 单价
  • 多效价的

第五章儿科疫苗市场：技术估算与趋势分析

  • 细分仪表板
  • 儿科疫苗市场：2023 年和 2030 年技术变化分析
  • 减毒活疫苗
  • 灭活疫苗
  • 次单位疫苗
  • 类毒素疫苗
  • 结合疫苗
  • 其他的

第六章儿科疫苗市场：按应用估算和趋势分析

  • 细分仪表板
  • 儿科疫苗市场：2023 年和 2030 年按应用分类的变化分析
  • 感染疾病
  • 癌症
  • 过敏
  • 肺炎链球菌感染
  • 流感
  • 麻疹、德国麻疹、腮腺炎 (MMR)
  • 其他用途

第七章儿科疫苗市场：区域估计和趋势分析

  • 2023 年及 2030 年儿科疫苗市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • AstraZeneca
    • Sanofi
    • GSK plc
    • Pfizer, Inc.
    • Zydus Group
    • Indian Immunologicals Ltd.
    • Serum Institute of India Pvt. Ltd.
    • Panacea Biotec
    • SINOVAC
    • BIO-MED
简介目录
Product Code: GVR-2-68038-279-2

Pediatric Vaccines Market Growth & Trends:

The global pediatric vaccines market size is expected to reach USD 49.46 billion by 2030, registering a CAGR of 4.1%, according to a new report by Grand View Research, Inc. Advancements in development of vaccines and new product launches are some of the major drivers of the market.

Increase in investments by companies to capture a larger market share is anticipated to propel growth. Some of the factors attributed to increase in investment are high growth prospects in the emerging market, immunization schedule mandated by doctors for children, and awareness programs led by UNICEF, WHO, and other healthcare organizations. Furthermore, increase in number of government initiatives for raising awareness about immunization is expected to boost the market for pediatric vaccines.

Advancements in development of novel adjuvants and therapeutic vaccines are expected to drive growth during the forecast period. Ongoing research in novel molecules targeted at specific mechanisms of action in the body is aimed at providing immunity against fatal diseases such as cancer and Zika virus disease. For instance, in June 2016, Inovio Pharmaceuticals, Inc. announced the initiation of phase I clinical trial for their Zika DNA vaccine named GLS-5700.

Pediatric Vaccines Market Report Highlights:

  • By type, monovalent emerged as the largest segment due to factors such as high usage and increase in initiatives for R&D activities supported by various governments.
  • Conjugate vaccines formed the dominant technology segment in terms of revenue in 2023. Higher adoption of these vaccines and increase in prevalence of infectious diseases contribute to its lead in the market for pediatric vaccines.
  • By application, the measles, mumps, and rubella (MMR) segment is projected to grow at the fastest CAGR of 6.1% over the forecast period. This is attributable to the fact that there are still cases of measles, mumps, and rubella which are characteristics of children who have not been vaccinated in areas with poor coverage.
  • North America held the largest revenue share in 2023. Its dominance in the market for pediatric vaccines is owing to factors such as local presence of major players in the industry and extensive R&D activities.
  • The Asia Pacific region is anticipated to witness lucrative growth over the next decade due to increase in prevalence of infectious diseases and a large target population.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Pediatric Vaccines Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Pediatric Vaccines Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Pediatric Vaccines Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Pediatric Vaccines Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Monovalent
    • 4.3.1. Monovalent Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Multivalent
    • 4.4.1. Multivalent Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pediatric Vaccines Market: Technology Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Pediatric Vaccines Market: Technology Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Live Attenuated Vaccines
    • 5.3.1. Live Attenuated Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Inactivated Vaccines
    • 5.4.1. Inactivated Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Subunit Vaccines
    • 5.5.1. Subunit Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Toxoid Vaccines
    • 5.6.1. Toxoid Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Conjugate Vaccines
    • 5.7.1. Conjugate Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Pediatric Vaccines Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Pediatric Vaccines Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Infectious Disease
    • 6.3.1. Infectious Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Cancer
    • 6.4.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Allergy
    • 6.5.1. Allergy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Pneumococcal Diseases
    • 6.6.1. Pneumococcal Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Influenza
    • 6.7.1. Influenza Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Measles, Mumps, and Rubella (MMR)
    • 6.8.1. Measles, Mumps, and Rubella (MMR) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.9. Other Application
    • 6.9.1. Other Application Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pediatric Vaccines Market: Regional Estimates & Trend Analysis

  • 7.1. Pediatric Vaccines Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. AstraZeneca
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Sanofi
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. GSK plc
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Pfizer, Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Zydus Group
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Indian Immunologicals Ltd.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Serum Institute of India Pvt. Ltd.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Panacea Biotec
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. SINOVAC
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. BIO-MED
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives